Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism

(2020) Masamoto Murakami et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

(2019) Hervé Bachelez et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

(2019) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis

(2019) Tadashi Terui et al.   JAMA Dermatology

Pustular psoriasis and related pustular skin diseases

(2018) H. Bachelez   BRITISH JOURNAL OF DERMATOLOGY

Clinical and genetic differences between pustular psoriasis subtypes

(2018) Sophie Twelves et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis

(2018) Tadashi Terui et al.   JAMA Dermatology

European consensus statement on phenotypes of pustular psoriasis

(2017) A.A. Navarini et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies

(2017) Rajkumar Ganesan et al.   mAbs

An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target

(2017) Satveer K. Mahil et al.   Science Translational Medicine

Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects

(2016) Inês Raposo et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

IL-1 and IL-36 are the dominant cytokines in Palmar Plantar Pustulosis

(2016) Andrew Johnston et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris

(2016) Robert Bissonnette et al.   PLoS One

Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients

(2015) Ting-Shun Wang et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking

(2014) Niovi Setta-Kaffetzi et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis

(2014) Trine Bertelsen et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Topical steroid-damaged skin

(2014) Anil Abraham et al.   INDIAN JOURNAL OF DERMATOLOGY

Ciclosporin Use During Pregnancy

(2013) Karolina Paziana et al.   DRUG SAFETY

Rare Pathogenic Variants in IL36RN Underlie a Spectrum of Psoriasis-Associated Pustular Phenotypes

(2013) Niovi Setta-Kaffetzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

(2011) Alexandros Onoufriadis et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Management of palmoplantar pustulosis: do we need to change?

(2011) U. Mrowietz et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

(2011) Slaheddine Marrakchi et al.   NEW ENGLAND JOURNAL OF MEDICINE